何玉先，1966年生，籍貫安徽蕭縣，病毒學(xué)家，病原生物學(xué)研究所研究員，博士生導(dǎo)師。1990-1993年在中國預(yù)防醫(yī)學(xué)科學(xué)院勞動衛(wèi)生與職業(yè)病學(xué)專業(yè)攻讀碩士學(xué)位，從事矽肺致病機(jī)制及治療研究。2005-2007年在德國烏爾姆大學(xué)醫(yī)學(xué)病毒學(xué)專業(yè)攻讀博士學(xué)位，從事艾滋病分子病毒學(xué)研究。1997-2008年曾任職美國洛克菲勒大學(xué)訪問學(xué)者、紐約大學(xué)博士后研究員和紐約血液中心助理研究員，主要研究艾滋病及新發(fā)重大傳染病研究。2008年4月回國任職病原生物學(xué)研究所研究員。

艾滋病病毒感染機(jī)制、抗病毒藥物及基因治療策略，新型冠狀病毒膜融合的分子機(jī)制及強(qiáng)效抑制劑研發(fā)

爆草黑丝美女|韩国19禁无遮挡啪啪无码网站|91精品国产自产精品男人的天堂|sm鞭打高潮喷水抽搐调教玩弄|果冻在线|日本大尺度吃奶呻吟视频|久久久久黄片|北条麻妃av免费观看|中文字幕一区二区人妻|亚洲最大天堂无码精品区,日韩 欧美 国产精品,国产肉丝袜在线观看,最爽无遮挡行房视频,成人H视频在线观看,糖心vlog冉冉,蜜桃产品一二三产区

1. Xue J#*, Chong H#, Zhu Y#, Zhang J, Tong L, Lu J, Chen T, Cong Z, Wei Q, He Y*. 2022. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell. 185(1): 131-44. (IF=66.850)

2. Zhu Y#, Dong X#, Liu N, Wu T, Chong H, Lei X, Ren L, Wang J*, He Y*. 2022. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. Emerg Microbes Infect. 11(1):1819-27. (IF=19.568)

3. Chen Y, Jin H*, Tang X, Li L, Geng X, Zhu Y, Chong H, He Y*. 2022. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy. Emerg Microbes Infect. 11(1):30-49. (IF=19.568)

4. Zhu Y#, Yu D#, Hu Y#, Wu T, Chong H, He Y*. 2021. SARS-CoV-2 derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther. 6(1):294. (IF=19.568)

5. Yu D#, Zhu Y#, Jiao T#, Wu T#, Xiao X, Qin B, Hu Y, Chong H, Lei X, Ren L, Cui S*, Wang J*, He Y*. 2021. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect. 10(1):1227-40. (IF=7.163)

6. Yu D#, Zhu Y#, Yan H#, Wu T, Chong H, He Y*. 2021. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 10(1):810-21. (IF=7.163)

7. Jin H, Tang X, Li L, Chen Y, Zhu Y, Chong H, He Y*. 2021. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cell Mol Immunol. 18(3): 660-74. (IF=11.530)

8. Zhu Y#, Yu D#, Han Y#, Yan H, Chong H, Ren L, Wang J*, Li T*, He Y*. 2020. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Sci Adv. 6(45): eabc9999. (IF=14.136)

9. Chong H#, Xue J#, Zhu Y#, Cong Z, Chen T, Wei Q, Qin C*, He Y*. 2019. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog. 15(2):e1007552. (IF=6.463)

10. He Y*, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q*. 2008. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci USA. 105(42):16332-7. (IF=9.380)